Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Eligibility Criteria

• * High Risk Group 1 (familial pancreatic cancer relatives):
• * \>/=55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
• * Come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
• * Have a first-degree relationship with at least one of the relatives with pancreatic cancer.
• * If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened.
• * High Risk Group 2 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~10% or higher):
• * \>/=40 years old and the Patient is a carrier of FAMMM (p16/CDKN2A) mutation regardless of family pancreas cancer history.
• * \>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and the Patient is a carrier of a known BRCA2, ATM, PALB2 mutation.
• * Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.
• * \>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and
• * The patient is a carrier of a known, BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.
• * Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.
• * Cohort A: Patients must have a pancreatic imaging abnormality that is being followed by pancreatic imaging surveillance (EUS and/or MRI and /or CT), such as a pancreatic cyst consistent with an IPMN or parenchymal abnormalities consistent with PanIN.
• * Cohort B: Patients must have clinical, radiographic, or histologic evidence of pancreatic cystic neoplasm with high-risk features warranting surgical resection per the discretion of the treating hepatobiliary surgeon.
• * Cohort B: Patients must have cystic fluid testing that demonstrates the presence of one of the six KRAS mutations included in the study vaccine.
• * Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
• * Ability to understand and willingness to sign a written informed consent document.
• * Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
• * Men must use acceptable form of birth control while on study.
• * If expected to require any other form of systemic or localized antineoplastic therapy while on study.
• * Within 4 weeks prior to first dose of study drug.
• * Within 4 weeks prior to first dose of study drug.
• * Any investigational device.
• * Has received a live vaccine.
• * Received any allergen hyposensitization therapy.
• * Any major surgery.
• * Infection with HIV or hepatitis B or C.
• * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements monoclonal antibody.
• * Has a diagnosis of immunodeficiency.
• * Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
• * Unwilling or unable to follow the study schedule for any reason.
• * Are pregnant or breastfeeding.